prnasiaMay 20, 2021
Tag: Ascentage , Lisaftoclax , pelcitoclax
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on the first-in-human study of the Bcl-2 inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory chronic lymphocytic lymphoma/small lymphocytic lymphoma (R/R CLL/SLL) and other hematologic malignancies has been published in the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting's official website. Results from this global Phase I study demonstrated an ORR of 85.7%, and favorable tolerability and safety profiles in patients with R/R CLL /SLL.
The updated results from this study will be released in an oral presentation at the ASCO Annual Meeting convening on June 4 to 8, 2021. This year, abstracts reporting on four clinical studies of the Ascentage Pharma's three apoptosis-target drug candidates have been selected for presentations at the ASCO Annual Meeting, and two have been selected for oral presentations.
"As a Bcl-2 inhibitor that has demonstrated efficacy, lisaftoclax is the second in the world and the first in China. These data of lisaftoclax suggest the potential for a safe, efficacious, and 'patient-friendly' treatment alternative for patients with R/R CLL and other hematologic malignancies," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Moreover, these results which will be presented at the 2021 ASCO Annual Meeting are a testament to our progress in advancing the research and development of apoptosis-targeted therapeutics. We will strive to further accelerate global clinical development programs of these novel therapeutics to benefit patients in China and around the world as early as possible."
Lisaftoclax is a novel, orally administered small-molecule Bcl-2‒selective inhibitor being developed by Ascentage Pharma. Lisaftoclax is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells. Lisaftoclax is the first China-developed Bcl-2 inhibitor entering clinical development in China. At present, lisaftoclax has been cleared and approved to enter multiple Phase Ib/II studies in the US, China, and Australia, and is being developed globally for the treatment of multiple hematologic malignancies.
Pelcitoclax is a novel, highly potent, small-molecule drug designed to restore apoptosis through selective inhibition of Bcl-2 and Bcl-xL proteins. Multiple Phase Ib/II studies of pelcitoclax as a single agent or in combinations for the treatment of a range of advanced tumors, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), are being conducted in China, Australia, and the US.
Ascentage Pharma (6855.HK) is a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong, S.A.R., China Limited with the stock code: 6855.HK.
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe and China. Olverembatinib (HQP1351), the company's core drug candidate, developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA. A New Drug Application (NDA) for olverembatinib has been submitted and subsequently granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) in China. To date, Ascentage Pharma has obtained a total of 11 ODDs from the US FDA for four of the company's investigational drug candidates.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: